No products in the cart.
-
Sale
Acecard 1.25 mgAcecard 1.25 mg indicated in the following cases: Hypertension; to lower blood pressure, as single-drug therapy or in combination with other antihypertensive agents. Congestive heart failure; also in combination with diuretics. Treatment of patients who- within the first few days after an acute myocardial infarction- have demonstrated clinical signs of congestive heart failure. ... Read moreAcecard 1.25 mg indicated in the following cases: Hypertension; to lower blood pressure, as single-drug therapy or in combination with other antihypertensive agents. Congestive heart failure; also in combination with diuretics. Treatment of patients who- within the first few days after an acute myocardial infarction- have demonstrated clinical signs of congestive heart failure. Treatment of non-diabetic or diabetic overt glomerular or incipient nephropathy. Reduction in the risk of myocardial infarction, stroke, or cardiovascular death in patients with an increased cardiovascular risk, such as manifest coronary heart disease (with or without a history of myocardial infarction), a history of stroke, a history of peripheral vascular disease, or diabetes mellitus that is accompanied by at least one other cardiovascular risk factor (microalbuminuria, hypertension, elevated total cholesterol levels, low high-density lipoprotein cholesterol levels, smoking). Theropeutic ClassAngiotensin-converting enzyme (ACE) inhibitorsPharmacologyAcecard 1.25 mg is an angiotensin converting enzyme (ACE) inhibitor, which after hydrolysis to Acecard 1.25 mgat, blocks the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. So, inhibition of ACE by Acecard 1.25 mg results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and decreased aldosterone secretion. Thus Acecard 1.25 mg exerts its antihypertensive activity. It is also effective in the management of heart failure and reduction of the risk of stroke, myocardial infarction and death from cardiovascular events. It is long acting and well tolerated; so, can be used in long term therapy.Dosage & Administration of Acecard 1.25 mgDosage of Acecard 1.25 mg must be adjusted according to the patient tolerance and response.Hypertension: For the management of hypertension in adults not receiving a diuretic, the usual initial dose of Acecard 1.25 mg is 1.25 - 2.5 mg once daily. Dosage generally is adjusted no more rapidly than at 2 week intervals. The usual maintenance dosage in adults is 2.5 - 20 mg daily given as a single dose or in 2 divided doses daily. If BP is not controlled with Acecard 1.25 mg alone, a diuretic may be added.Congestive heart failure after myocardial infarction: In this case, Acecard 1.25 mg therapy may be initiated as early as 2 days after myocardial infarction. An initial dose of 2.5 mg twice daily is recommended, but if hypotension occurs, dose should be reduced to 1.25 mg twice daily. Therapy is then titrated to a target daily dose of 5 mg twice daily. Prevention of major cardiovascular events: In this case, the recommended dose is 2.5 mg once daily for the first week of therapy and 5 mg once daily for the following 3 weeks; dosage then may be increased, as tolerated, to a maintenance dosage of 10 mg once daily.Dosage of Acecard 1.25 mgDosage of Acecard 1.25 mg must be adjusted according to the patient tolerance and response.Hypertension: For the management of hypertension in adults not receiving a diuretic, the usual initial dose of Acecard 1.25 mg is 1.25-2.5 mg once daily. Dosage generally is adjusted no more rapidly than at 2 week intervals. The usual maintenance dosage in adults is 2.5-20 mg daily given as a single dose or in 2 divided doses daily. If BP is not controlled with Acecard 1.25 mg alone, a diuretic may be added.Congestive heart failure after myocardial infarction: In this case, Acecard 1.25 mg therapy may be initiated as early as 2 days after myocardial infarction. An initial dose of 2.5 mg twice daily is recommended, but if hypotension occurs, dose should be reduced to 1.25 mg twice daily. Therapy is then titrated to a target daily dose of 5 mg twice daily. Prevention of major cardiovascular events: In this case, the recommended dose is 2.5 mg once daily for the first week of therapy and 5 mg once daily for the following 3 weeks; dosage then may be increased, as tolerated, to a maintenance dosage of 10 mg once daily.Dosage in renal impairment: For patients with hypertension and renal impairment: The recommended initial dose is 1.25 mg Acecard 1.25 mg once daily. Subsequent dosage should be titrated according to individual tolerance and BP response, up to a maximum of 5 mg daily. For patients with heart failure and renal impairment: The recommended dose is 1.25 mg once daily. The dose may be increased to 1.25 mg twice daily and up to a maximum dose of 2.5 mg twice daily depending upon clinical response and tolerability. Administration of Acecard 1.25 mgAcecard 1.25 mg tablets have to be swallowed with sufficient amounts of liquid. The tablets must not be chewed or crushed. Absorption of Acecard 1.25 mg is not significantly affected by food. Acecard 1.25 mg may, therefore, be taken before, during or after a meal.Interaction of Acecard 1.25 mgConcomitant administration with diuretics may lead to serious hypotension and in addition dangerous hyperkalemia with potassium sparing diuretics. Concomitant therapy with lithium may increase the serum lithium concentration. Reduction in BP may affect the ability to drive and operate machinery and this may be exacerbated by alcohol. NSAIDs may reduce the antihypertensive effect of Acecard 1.25 mg and cause deterioration of renal function.ContraindicationsAcecard 1.25 mg must not be used in patients with hypersensitivity to Acecard 1.25 mg, to any other ACE inhibitor, or any of the excipients of Acecard 1.25 mg. in patients with a history of angioedema. concomitantly with sacubitril/valsartan therapy. Do not initiate Acecard 1.25 mg until sacubitril/valsartan is eliminated from the body. In case of switch from Acecard 1.25 mg to sacubitril/valsartan, do not start sacubitril/valsartan until Acecard 1.25 mg is eliminated from the body. in patients with haemodynamically relevant renal artery stenosis, bilateral or unilateral in the single kidney. in patients with hypotensive or haemodynamically unstable states. with aliskiren-containing medicines in patients with diabetes or with moderate to severe renal impairment (creatinine clearance <60 ml/min). with angiotensin II receptor antagonists (AIIRAs) in patients with diabetic nephropathy. during pregnancy. Concomitant use of ACE inhibitors and extracorporeal treatments leading to contact of blood with negatively charged surfaces must be avoided, since such use may lead to severe anaphylactoid reactions. Such extracorporeal treatments include dialysis or haemofiltration with certain high-fux (e.g. polyacrylonitril) membranes and low-density lipoprotein apheresis with dextran sulfate.Side Effects of Acecard 1.25 mgAcecard 1.25 mg is generally well tolerated. Dizziness, headache, fatigue and asthenia are commonly reported side effects. Other side effects occurring less frequently include symptomatic hypotension, cough, nausea, vomiting, diarrhoea, rash, urticaria, oliguria, anxiety, amnesia etc. Angioneurotic oedema, anaphylactic reactions and hyperkalaemia have also been reported rarely.Pregnancy & LactationIf pregnancy is detected, Acecard 1.25 mg should be discontinued as early as possible unless continued use is considered life saving. Acecard 1.25 mg should not be used during lactation.Precautions & WarningsAcecard 1.25 mg should be used with caution in patients with impaired renal function, hyperkalaemia, hypotension, and impaired hepatic function.Overdose Effects of Acecard 1.25 mgSign and symptom: Overdosage may cause excessive peripheral vasodilatation (with marked hypotension, shock), bradycardia, electrolyte disturbances, and renal failure.Management: Primary detoxifcation by, for example, gastric lavage, administration of adsorbents, sodium sulfate; (if possible during the frst 30 minutes). In the event of hypotension administration of ?1-adrenergic agonists (e.g. norepinephrine, dopamine) or angiotensin II (angiotensinamide), which is usually available only in scattered research laboratories, must be considered in addition to volume and salt substitution.Storage ConditionsStore at 30? or below, protect from light. Keep out of the reach of children. Do not use later than the date of expiry. To be dispensed only on the prescription of a registered physician.Use In Special PopulationsDosage in renal impairment: For the patients with hypertension and renal impairment, the recommended initial dose is 1.25 mg Acecard 1.25 mg once daily. Subsequent dosage should be titrated according to individual tolerance and BP response, up to a maximum of 5 mg daily. For the patients with heart failure and renal impairment, the recommended dose is 1.25 mg once daily. The dose may be increased to 1.25 mg twice daily and up to a maximum dose of 2.5 mg twice daily depending upon clinical response and tolerability. Use in children: No information is yet available on the use of Acecard 1.25 mg in children.Drug ClassesAngiotensin-converting enzyme (ACE) inhibitorsMode Of ActionAcecard 1.25 mg is an angiotensin converting enzyme (ACE) inhibitor, which after hydrolysis to Acecard 1.25 mgat, blocks the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. So, inhibition of ACE by Acecard 1.25 mg results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and decreased aldosterone secretion. Thus Acecard 1.25 mg exerts its antihypertensive activity. It is also effective in the management of heart failure and reduction of the risk of stroke, myocardial infarction and death from cardiovascular events. It is long acting and well tolerated; so, can be used in long term therapy.PregnancyAcecard 1.25 mg must not be taken during pregnancy. Therefore, pregnancy must be excluded before starting treatment. Pregnancy must be avoided in cases where treatment with ACE inhibitors is indispensable. If the patient intends to become pregnant, treatment with ACE inhibitors must be discontinued, i.e. replaced by another form of treatment. If the patient becomes pregnant during treatment, medication with Acecard 1.25 mg must be replaced as soon as possible by a treatment regimen without ACE inhibitors. Otherwise, there is a risk of harm to the fetus. Acecard 1.25 mg is not recommended during breastfeeding.Pediatric UsesElderly: A reduced initial dose of 1.25 mg Acecard 1.25 mg daily must be considered.Hepatic impairment: Treatment in these patients must therefore be initiated only under close medical supervision. The maximum permitted daily dose in such cases is 2.5 mg Acecard 1.25 mg.Renal impairment: With a creatinine clearance between 50 and 20 ml/min per 1.73 m2 body surface area, the initial daily dose is generally 1.25 mg Acecard 1.25 mg. The maximum permitted daily dose, in this case, is 5 mg Acecard 1.25 mg. Patients with incompletely corrected fuid or salt depletion, in patients with severe hypertension, as well as in patients in whom a hypotensive reaction would constitute a particular risk, (e.g., with relevant stenoses of the coronary vessels or those supplying the brain) A reduced initial dose of 1.25 mg Acecard 1.25 mg daily must be considered.Patients pretreated with a diuretic: Consideration must be given to discontinuing the diuretic for at least 2 to 3 days or- depending on the duration of action of the diuretic- longer before starting treatment with Acecard 1.25 mg, or at least to reducing the diuretic dose. The initial daily dose in patients previously treated with a diuretic is generally 1.25 mg Acecard 1.25 mg.Acecard1.25 mg
Original price was: ₦1,650.00.₦1,518.00Current price is: ₦1,518.00.
5.07423
0.00001
0.00044
0.01008
1.14011
-
SaleAcepril 10 mgHypertension: Acepril 10 mg is indicated for the treatment of?hypertension?in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal?cardiovascular?events, primarily strokes ... Read moreHypertension: Acepril 10 mg is indicated for the treatment of?hypertension?in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal?cardiovascular?events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of?antihypertensive?drugs from a wide variety of pharmacologic classes.Control of?high blood pressure?should be part of comprehensive cardiovascular risk management, including, as appropriate,?lipid control, diabetes?management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program?s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of?stroke, but reductions in?myocardial infarction?and cardiovascular mortality also have been seen regularly.Elevated?systolic?or?diastolic?pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or?hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on?angina,?heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.Acepril 10 mg may be administered alone or with other antihypertensive agents.Heart Failure: Acepril 10 mg is indicated to reduce signs and symptoms of heart failure in patients who are not responding adequately to?diuretics?and digitalis.Acute Myocardial Infarction: Acepril 10 mg is indicated for the reduction of mortality in treatment of hemodynamically stable patients within 24 hours of?acute myocardial infarction. Patients should receive, as appropriate, the standard recommended treatments such as thrombolytics, aspirin and beta-blockersTheropeutic ClassAngiotensin-converting enzyme (ACE) inhibitorsPharmacologyAcepril 10 mg competitively inhibits ACE from converting angiotensin I to angiotensin II (a potent vasoconstrictor) resulting in increased plasma renin activity and reduced aldosterone (a hormone that causes water and Na retention) secretion. This promotes vasodilation and BP reduction.Dosage of Acepril 10 mgOral (Adult)- Hypertension: Initially, 10 mg/day, 1st dose given preferably at bedtime to avoid precipitous fall in BP. Patient with renovascular HTN, volume depletion, severe HTN: Initially, 2.5-5 mg once daily. Patient on diuretic: Initially, 5 mg once daily. Maintenance: 20 mg once daily, up to 80 mg/day may be given if needed.Diabetic nephropathy: Hypertensive type 2 diabetics with microalbuminuria: 10 mg once daily, may increase to 20 mg once daily to achieve a sitting diastolic BP Heart failure: As adjunct: Initially, 2.5 or 5 mg/day, increased by increments of ?10 mg at intervals of at least 2 wk to max maintenance dose of 40 mg/day.Post-myocardial infarction: Initially, 5 mg once daily for 2 days started within 24 hr of the onset of symptoms. Increase to 10 mg once daily. Patients with low systolic BP: Initially, 2.5 mg once daily. Oral (Child)- Hypertension: ?6 yr Initially, 0.07 mg/kg, up to 5 mg once daily.Administration of Acepril 10 mgMay be taken with or without food.Interaction of Acepril 10 mgMay enhance hypotensive effect with diuretics. May increase risk of renal function deterioration and decrease antihypertensive effect with NSAIDs. May increase serum levels and toxicity of lithium. Increased risk of hyperkalaemia with K-sparing diuretics and K supplements. May increase nitritoid reactions of gold Na thiomalate.ContraindicationsHistory of angioedema related to previous ACE inhibitor treatment, hereditary or idiopathic angioedema. Concomitant use with aliskiren in patients with diabetes or renal impairment. Pregnancy. Children with GFR <30 mL/min/1.73 m2.Side Effects of Acepril 10 mgHeadache, fatigue, persistent and non-productive cough, chest and abdominal pain, dizziness, nausea, vomiting, diarrhoea, upper resp tract infection, asthenia, rash, orthostatic effects, hypotension, renal dysfunction, hyperkalaemia, intestinal angioedema; increased BUN and serum creatinine levels.Pregnancy & LactationCategory D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).Precautions & WarningsBilateral renal artery stenosis or a single kidney with unilateral renal artery stenosis. Patients with collagen vascular disease, acute MI at risk of further haemodynamic deterioration, angioedema unrelated to ACE inhibitor therapy, aortic stenosis and hypertrophic cardiomyopathy. Increased risk of angioedema in black patients. Renal impairment. Lactation. Childn <6 yr.Overdose Effects of Acepril 10 mgSymptoms: Hypotension, tachycardia, circulatory shock, palpitations, bradycardia, hyperventilation, renal failure, electrolyte disturbances, anxiety, dizziness and cough. Management: Normal saline IV infusion may be used. Perform haemodialysis, emesis, gastric lavage, admin of absorbents and Na sulfate if recently taken. Consider admin of angiotensin II infusion and/or IV catecholamines if available.Storage ConditionsStore at below 25? C.Use In Special PopulationsAdult: CrCl 10-30 ml/min: Initially, 2.5-5 mg once daily. CrCl 31-80 ml/min: Initially 5-10 mg once daily. Dose can be adjusted up to max 40 mg once daily based on patient's response. Child: Do not give if GFR <30 mL/min/1.73 m2.Drug ClassesAngiotensin-converting enzyme (ACE) inhibitorsMode Of ActionAcepril 10 mg competitively inhibits ACE from converting angiotensin I to angiotensin II (a potent vasoconstrictor) resulting in increased plasma renin activity and reduced aldosterone (a hormone that causes water and Na retention) secretion. This promotes vasodilation and BP reduction.PregnancyCategory D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).Pediatric UsesAdult: CrCl 10-30 ml/min: Initially, 2.5-5 mg once daily. CrCl 31-80 ml/min: Initially 5-10 mg once daily. Dose can be adjusted up to max 40 mg once daily based on patient's response. Child: Do not give if GFR <30 mL/min/1.73 m2.
Acepril10 mg
Original price was: ₦5,390.00.₦4,851.00Current price is: ₦4,851.00.
16.21547
0.00004
0.00139
0.03222
3.64341
-
SaleAcepril 5 mgHypertension: Acepril 5 mg is indicated for the treatment of?hypertension?in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal?cardiovascular?events, primarily strokes ... Read moreHypertension: Acepril 5 mg is indicated for the treatment of?hypertension?in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal?cardiovascular?events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of?antihypertensive?drugs from a wide variety of pharmacologic classes.Control of?high blood pressure?should be part of comprehensive cardiovascular risk management, including, as appropriate,?lipid control, diabetes?management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program?s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of?stroke, but reductions in?myocardial infarction?and cardiovascular mortality also have been seen regularly.Elevated?systolic?or?diastolic?pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or?hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on?angina,?heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.Acepril 5 mg may be administered alone or with other antihypertensive agents.Heart Failure: Acepril 5 mg is indicated to reduce signs and symptoms of heart failure in patients who are not responding adequately to?diuretics?and digitalis.Acute Myocardial Infarction: Acepril 5 mg is indicated for the reduction of mortality in treatment of hemodynamically stable patients within 24 hours of?acute myocardial infarction. Patients should receive, as appropriate, the standard recommended treatments such as thrombolytics, aspirin and beta-blockersTheropeutic ClassAngiotensin-converting enzyme (ACE) inhibitorsPharmacologyAcepril 5 mg competitively inhibits ACE from converting angiotensin I to angiotensin II (a potent vasoconstrictor) resulting in increased plasma renin activity and reduced aldosterone (a hormone that causes water and Na retention) secretion. This promotes vasodilation and BP reduction.Dosage of Acepril 5 mgOral (Adult)- Hypertension: Initially, 10 mg/day, 1st dose given preferably at bedtime to avoid precipitous fall in BP. Patient with renovascular HTN, volume depletion, severe HTN: Initially, 2.5-5 mg once daily. Patient on diuretic: Initially, 5 mg once daily. Maintenance: 20 mg once daily, up to 80 mg/day may be given if needed.Diabetic nephropathy: Hypertensive type 2 diabetics with microalbuminuria: 10 mg once daily, may increase to 20 mg once daily to achieve a sitting diastolic BP Heart failure: As adjunct: Initially, 2.5 or 5 mg/day, increased by increments of ?10 mg at intervals of at least 2 wk to max maintenance dose of 40 mg/day.Post-myocardial infarction: Initially, 5 mg once daily for 2 days started within 24 hr of the onset of symptoms. Increase to 10 mg once daily. Patients with low systolic BP: Initially, 2.5 mg once daily. Oral (Child)- Hypertension: ?6 yr Initially, 0.07 mg/kg, up to 5 mg once daily.Administration of Acepril 5 mgMay be taken with or without food.Interaction of Acepril 5 mgMay enhance hypotensive effect with diuretics. May increase risk of renal function deterioration and decrease antihypertensive effect with NSAIDs. May increase serum levels and toxicity of lithium. Increased risk of hyperkalaemia with K-sparing diuretics and K supplements. May increase nitritoid reactions of gold Na thiomalate.ContraindicationsHistory of angioedema related to previous ACE inhibitor treatment, hereditary or idiopathic angioedema. Concomitant use with aliskiren in patients with diabetes or renal impairment. Pregnancy. Children with GFR <30 mL/min/1.73 m2.Side Effects of Acepril 5 mgHeadache, fatigue, persistent and non-productive cough, chest and abdominal pain, dizziness, nausea, vomiting, diarrhoea, upper resp tract infection, asthenia, rash, orthostatic effects, hypotension, renal dysfunction, hyperkalaemia, intestinal angioedema; increased BUN and serum creatinine levels.Pregnancy & LactationCategory D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).Precautions & WarningsBilateral renal artery stenosis or a single kidney with unilateral renal artery stenosis. Patients with collagen vascular disease, acute MI at risk of further haemodynamic deterioration, angioedema unrelated to ACE inhibitor therapy, aortic stenosis and hypertrophic cardiomyopathy. Increased risk of angioedema in black patients. Renal impairment. Lactation. Childn <6 yr.Overdose Effects of Acepril 5 mgSymptoms: Hypotension, tachycardia, circulatory shock, palpitations, bradycardia, hyperventilation, renal failure, electrolyte disturbances, anxiety, dizziness and cough. Management: Normal saline IV infusion may be used. Perform haemodialysis, emesis, gastric lavage, admin of absorbents and Na sulfate if recently taken. Consider admin of angiotensin II infusion and/or IV catecholamines if available.Storage ConditionsStore at below 25? C.Use In Special PopulationsAdult: CrCl 10-30 ml/min: Initially, 2.5-5 mg once daily. CrCl 31-80 ml/min: Initially 5-10 mg once daily. Dose can be adjusted up to max 40 mg once daily based on patient's response. Child: Do not give if GFR <30 mL/min/1.73 m2.Drug ClassesAngiotensin-converting enzyme (ACE) inhibitorsMode Of ActionAcepril 5 mg competitively inhibits ACE from converting angiotensin I to angiotensin II (a potent vasoconstrictor) resulting in increased plasma renin activity and reduced aldosterone (a hormone that causes water and Na retention) secretion. This promotes vasodilation and BP reduction.PregnancyCategory D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).Pediatric UsesAdult: CrCl 10-30 ml/min: Initially, 2.5-5 mg once daily. CrCl 31-80 ml/min: Initially 5-10 mg once daily. Dose can be adjusted up to max 40 mg once daily based on patient's response. Child: Do not give if GFR <30 mL/min/1.73 m2.
Acepril5 mg
Original price was: ₦3,080.00.₦2,772.00Current price is: ₦2,772.00.
9.26598
0.00003
0.00080
0.01841
2.08195
-
SaleAcilog Mix 30%+70%Biphasic Insulin Aspart (rDNA) is indicated to improve glycemic control in adults and children with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.CompositionEach ml suspension contains Insulin Aspart (rDNA) 100 units (equivalent to 3.5 mg) as 30% soluble Insulin Aspart and 70% Insulin Aspart Protamine suspensionTheropeutic ClassCombination InsulinPharmacology30% Insulin Aspart and 70% Insulin Aspart Protamine (rDNA) is a human insulin analog suspension containing 30 % soluble Insulin Aspart and 70% Insulin Aspart Protamine crystals. This is a blood glucose lowering agent with an earlier onset and an intermediate duration of action. Insulin Aspart is homologous with regular human insulin with the exception of a single substitution of the proline by aspartic acid in position B28, and is produced by recombinant DNA technology utilizing Saccharomyces cerevisiae (baker?s yeast).Primary function of insulin, including Insulin Aspart, is regulation of glucose metabolism. Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, primarily by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, and enhances protein synthesis.Dosage of Acilog Mix 30%+70%The dosage of insulin aspart must be individualized.Subcutaneous injection: insulin aspart should generally be given immediately (within 5-10 minutes) prior to the start of a meal.Use in pumps: Change the insulin aspart in the reservoir at least every 6 days, change the infusion set, and the infusion set insertion site at least every 3 days. insulin aspart should not be mixed with other insulins or with a diluent when it is used in the pump.Intravenous use: insulin aspart should be used at concentrations from 0.05 U/mL to 1.0 U/mL insulin aspart in infusion systems using polypropylene infusion bags. insulin aspart has been shown to be stable in infusion fluids such as 0.9% sodiumchloride.Administration of Acilog Mix 30%+70%Before going for administration of Biphasic Insulin Aspart (rDNA) please follow the below mentioned check list: Insulin syringe of the right size (100 units/ml) Prescribed type of insulin injection Check the expiry date on Biphasic Insulin Aspart (rDNA) vial Ensure that the flip off cap on the Biphasic Insulin Aspart (rDNA) vial is intact After that follow the below mentioned instructions: Wash your hands carefully. Shake or roll the vial 10 times to completely Mix the insulin. lnspect the vial. Vial should appear white and cloudy after mixing. When using a new vial, flip off the plastic protective cap, but do not remove the stopper. The tip of the vial should be wiped with an alcohol swab. Draw air into the syringe equal to your insulin dose. Insert needle into vial through rubber top & push plunger to empty the air into the vial. Turn the bottle and syringe upside down. Hold the bottle and syringe firmly in one hand and shake gently. Make sure that the tip of the needle is in the liquid; withdraw the correct dose of insulin into the syringe. Before removing the needle from the vial, check the insulin syringe for air bubbles, which reduces the amount of insulin in it, if bubbles are present, hold the insulin straight up and tap its side until the bubbles float to the top. Push them out with the plunger and withdraw the correct dose again. Lightly pinch up the skin, holding the syringe like a pencil. Insert the needle into the skin & push the plunger slowly. Make sure that the needle is all the way in. Wait for 5 seconds & pull out the syringe. Do not rub the area. Interaction of Acilog Mix 30%+70%A number of substances affect glucose metabolism and may require dose adjustment and particularly close monitoring.The following are examples that may increase the blood glucose lowering effect and susceptibility to hypoglycemia: oral anti-diabetic products, pramlintide and angiotensin converting enzyme (ACE) inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, propoxyphene, salicylates and sulfonamide antibiotics.The following substances are examples that may reduce the blood glucose lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents, isoniazid, phenothiazine derivatives, somatropin, estrogens, progestogens, atypical antipsychotics and danazol. Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin. Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia.ContraindicationsBiphasic Insulin Aspart (rDNA) is contraindicated During episodes of hypoglycemia In patients with hypersensitivity to Insulin Aspart or any of its excipients. Side Effects of Acilog Mix 30%+70%Side effects of Insulin Aspart are hypoglycemia, lipodystrophy, weight gain, peripheral edema.Pregnancy & LactationPregnancy category B. Careful monitoring of glucose control is essential in such patients because insulin requirements change during different stages of pregnancy. Therefore female patients should be advised to tell their physician if they intend to become or if they become pregnant while taking insulin aspartLactation: It is unknown whether Insulin Aspart is excreted in human milk as occurs with human insulin. There are no adequate and well-controlled studies of the use of insulin aspart in lactating women. Lactating Women may require adjustments of their insulin doses.Precautions & WarningsDose adjustment and monitoring: Blood glucose should be monitored in all patients treated with insulin. Insulin regimens should be modified cautiously and only under medical supervision. Renal or hepatic impairment: Reduction in the Insulin Aspart dose may require in these cases.Overdose Effects of Acilog Mix 30%+70%Insulin Aspart overdose may result in hypoglycemia. Mild episodes of hypoglycemia can usually be treated with oral carbohydrates. Severe hypoglycemia may be treated with parenteral glucose or injections of glucagon. Adjustments in drug dosage, meal patterns, or exercise may be needed.Storage ConditionsStore at 2?C to 8?C in a refrigerator. Do not freeze. In case of insulin for recent use need not be refrigerated, try to keep it in a cool place and keep away from heat and light. The insulin in use can be kept under the room temperature for a month.Use In Special PopulationsPediatric: Has not been studied in children with type 2 diabetes. Has not been studied in children with type 1 diabetes <2 years of age
Acilog Mix30%+70%
Original price was: ₦24,750.00.₦23,512.50Current price is: ₦23,512.50.
78.59541
0.00022
0.00675
0.15618
17.65938
-
SaleAcilog 100 IU/mlAcilog 100 IU/ml is an insulin analog indicated to improve glycemic control in patients with diabetes mellitus.CompositionEach ml solution contains 100 IU (equivalent to 3.50 mg) Insulin Aspart (rDNA).Theropeutic ClassRapid Acting InsulinPharmacologyThe primary activity of Insulin Aspart is the regulation of glucose metabolism. Insulin Aspart bind to the insulin receptors on muscle and fat cells and lower blood glucose by facilitating the cellular uptake of glucose and simultaneously inhibiting the output of glucose from the liver.Dosage of Acilog 100 IU/mlInsulin Aspart has a faster onset and a shorter duration of action than soluble human insulin. Due to the faster onset of action, Insulin Aspart should generally be given immediately before a meal. When necessary Insulin Aspart may be given soon after a meal.Dosage of Insulin Aspart is individual and determined on the basis of the physician's advice in accordance with the needs of the patient. It should normally be used in combination with long-acting insulin given at least once a day.The individual insulin requirement is usually between 0.5 and 1.0 IU/kg/day in adults and children over 2 years of age. In a meal-related treatment 50-70% of this requirement may be provided by Insulin Aspart and the remainder by long-acting insulin. Adjustment of dosage may also be necessary if patients undertake increased physical activity or change their usual diet. Exercise taken immediately after a meal may increase the risk of hypoglycaemia.Subcutaneous Injection: Insulin Aspart should be administered by subcutaneous injection in the abdominal region, buttocks, thigh, or upper arm. Because Insulin Aspart has a more rapid onset and a shorter duration of activity than human regular insulin, it should be injected immediately (within 5-10 minutes) before a meal Continuous Subcutaneous Insulin Infusion (CSII) by External Pump Insulin Aspart can also be infused subcutaneously by an external insulin pump. The initial programming of the external insulin infusion pump should be based on the total daily insulin dose of the previous regimen. Approximately 50% of the total dose is usually given as meal-related boluses of Insulin Aspart and the remainder is given as a basal infusion. When used with an infusion pump Insulin Aspart should not be mixed with any other insulin.Intravenous Use: Insulin Aspart can be administered intravenously under medical supervision for glycemic control with close monitoring of blood glucose and potassium levels to avoid hypoglycemia and hypokalemia. For intravenous use, Insulin Aspart should be used at concentrations from 0.05 IU/mL to 1.0 IU/mL insulin aspart in infusion systems using polypropylene infusion bags. Insulin Aspart has been shown to be stable in infusion fluids such as 0.9% sodium chloride.Administration of Acilog 100 IU/mlInstructions to be given to the patient before injecting this Insulin: According to the instruction given with ConviPen, insert the cartridge into the pen correctly & equip the needle Gently turn the pen upside down for 8-10 times until the insulin in the cartridge becomes uniformly mixed suspension Remove the needle cap, discharge air bubbles in the catridge Adjust the dosage button to get correct dose & inject to the specific site In order to avoid cross contamination, do not let the needle touch anything during the process of preparation. Interaction of Acilog 100 IU/mlA number of drugs affect glucose metabolism and may require dose adjustment. The following substances may reduce the Insulin as well as Insulin Aspart requirements: Oral anti-diabetic products, angiotensin converting enzyme (ACE) inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, propoxyphene, pentoxifylline, salicylates and sulfonamide antibiotics.The following substances may increase the Insulin as well as Insulin Aspart requirements: Thiazides, glucocorticoids, thyroid hormones, beta-sympathomimetics, growth hormone and danazol. Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood glucose lowering effect of insulin.Side Effects of Acilog 100 IU/mlSide effects of Insulin Aspart are hypoglycemia, allergic reactions, injection site reaction, lipodystrophy, pruritus and rash.Pregnancy & LactationPregnancy category B. There are no restrictions on treatment with Acilog 100 IU/ml during lactation. Insulin treatment of the nursing mother should not affect the baby. However, dosage may need to be adjusted.Precautions & WarningsDose adjustment and monitoring: Blood glucose should be monitored in all patients treated with insulin. Insulin regimens should be modified cautiously and only under medical supervisionOverdose Effects of Acilog 100 IU/mlA specific overdose for insulin cannot be defined, however, hypoglycaemia may develop over sequential stages if too high doses relative to the patient?s requirement are administered. Mild hypoglycaemic episodes can be treated by oral administration of glucose or sugary products. Severe hypoglycaemic episodes, where the patient has become unconscious, can be treated by glucagon (0.5 to 1 mg) given intramuscularly or subcutaneously. Glucose must also be given intravenously if the patient does not respond to glucagon within 10 to 15 minutes. Upon regaining consciousness administration of oral carbohydrate is recommended for the patient in order to prevent relapse.Storage ConditionsStore at 2?C to 8?C in a refrigerator. Do not freeze. Protect from light.Drug ClassesRapid Acting InsulinMode Of ActionThe primary activity of Insulin Aspart is the regulation of glucose metabolism. Insulin Aspart bind to the insulin receptors on muscle and fat cells and lower blood glucose by facilitating the cellular uptake of glucose and simultaneously inhibiting the output of glucose from the liver.PregnancyPregnancy category B. There are no restrictions on treatment with Acilog 100 IU/ml during lactation. Insulin treatment of the nursing mother should not affect the baby. However, dosage may need to be adjusted.
Acilog100 IU/ml
Original price was: ₦45,375.00.₦43,106.25Current price is: ₦43,106.25.
144.09158
0.00040
0.01238
0.28632
32.37553
-
SaleAcliz Plus 25 mg+50 mgPrevention and treatment of nausea, vomiting, dizziness, motion sickness, radiation sickness and vertigo associated with diseases of the vestibular system (e.g. Meniere's syndrome, labyrinthitis and other vestibular disturbances).Theropeutic ClassAnti-emetic drugsPharmacologyMeclizine Hydrochloride prevents nausea and vomiting by reducing the activity of the center in the brain that controls nausea. It also prevents motion sickness by reducing excitability of neurons in the vestibular region of the brain. Pyridoxine Hydrochloride (vit. B6), either alone or combination has been used to prevent nausea and vomiting due to its antiemetic properties.Dosage & Administration of Acliz Plus 25 mg+50 mgNausea and vomiting during pregnancy: 1 tablet 1-2 times daily (after taking food) or as directed by the physician. Nausea and vomiting after surgery: 1-2 tablets daily.Nausea and vomiting induced by irradiation: 1 tablet (shortly before or after the irradiation). Motion sickness: 1-2 tablets one hour prior to journey. This dose may be repeated every 24 hours, if required.Vertigo associated with vestibular system diseases: 1 tablet 2 times daily or as required.Dosage of Acliz Plus 25 mg+50 mgAdult and Children 12 years of age & over: Nausea and vomiting: 25-50 mg daily or as directed by a physician. Motion sickness: Take an initial dose of 25-50 mg, 1 hour prior to travel. May repeat the dose every 24 hours for the duration of the journey. Radiation sickness: 50 mg administered 2-12 hours prior to radiation treatment. Vertigo: 25-100 mg daily in divided doses. Prevention of nausea and vomiting associated with emergency contraceptive pill (ECP): 25-50 mg, 1 hour before first ECP dose; repeat if needed in 24 hours. The safety and efficacy for use in children less than 12 years of age have not been established.Interaction of Acliz Plus 25 mg+50 mgThe CNS depressant effects of Meclizine can be potentiated by concurrent use of Ethanol or other CNS depressant agents such as Benzodiazepines, Barbiturates, Tricyclic antidepressants, opiate agonists, skeletal muscle relaxants and antihistamines. Concurrent use of other anticholinergics can potentiate the anticholinergic effects of Meclizine. Meclizine can increase the absorption of digoxin by decreasing gastrointestinal motility.ContraindicationsMeclizine Hydrochloride and Pyridoxine Hydrochloride is contraindicated in patients who are hypersensitive to these ingredients.Side Effects of Acliz Plus 25 mg+50 mgDrowsiness, dry mouth and, on rare occasions, blurred vision have been reported.Pregnancy & LactationThere is no evidence of adverse effects of this combination on pregnancy or on the health of the fetus or neonate. But account should be taken with the use of antihistamines to just before the parturition. Pyridoxine is considered as safe in pregnancy. Pyridoxine is excreted in human milk but meclizine is unknown whether it is excreted or not. So, this combination may be indicated during lactation, if clearly needed.Precautions & WarningsPatients should be warned that Meclizine Hydrochloride may impair their ability to perform hazardous activities requiring mental alertness or physical coordination (e.g., operating machinery, driving a motor vehicle). Patients should avoid alcoholic beverages while taking this drug. Due to its potential anticholinergic action, this drug should be used with caution in patients with asthma, glaucoma or enlargement of the prostate gland.Overdose Effects of Acliz Plus 25 mg+50 mgSymptoms: Extreme excitability, seizures, drowsiness and hallucinations.Treatment: Appropriate supportive and symptomatic treatment. Consider dialysisStorage ConditionsKeep below 30?C temperature, away from light & moisture. Keep out of the reach of children.Drug ClassesAnti-emetic drugsMode Of ActionMeclizine is a piperazine-derivative antihistamine that is used as an antiemetic. It has antiemetic, anticholinergic and antihistaminic properties. It reduces the sensitivity of the labyrinthine apparatus. The action may be mediated through nerve pathways to the vomiting center (VC) from the chemoreceptor trigger zone (CTZ), peripheral nerve pathways, the VC, or other CNS centers. Pyridoxine is vitamin B-6. It has been added to enhance the anti-emetic effects & as a dietary suppliment.PregnancyPregnancy Category B. Large-scale human studies have not demonstrated adverse fetal effects. It has been suggested that based on available data, Meclizine presents the lowest risk of teratogenicity and is the drug of first choice in treating nausea and vomiting during pregnancy. Safety for use in the nursing mother has not been established.
Acliz Plus25 mg+50 mg
Original price was: ₦192.50.₦174.90Current price is: ₦174.90.
0.58464
0.00000
0.00005
0.00116
0.13136
-
SaleAcos 500 mgAcos 500 mg is prescribed for infections (produced by susceptible organisms) in the upper respiratory tract, including sinusitis and pharyngitis/tonsillitis, the lower respiratory tract, including bronchitis and pneumonia, the otitis media, and the skin and soft tissue. Acos 500 mg is recommended for the treatment of non-gonococcal urethritis and cervicitis caused by Chlamydia trachomatis in sexually transmitted illnesses in both men and women.Theropeutic ClassMacrolidesPharmacologyAcos 500 mg belongs to the macrolide subclass of antibiotics known as azalide. In order to prevent microbial protein synthesis, Acos 500 mg binds to the 50s ribosomal subunit of susceptible species. Moraxella catarrhalis, anaerobes such as Bacteroides fragilis, Escherichia coli, Bordetella pertussis, Bordetella parapertussis, Borrelia burgdorferi, Haemophilus ducreyi, and Neisseria gonorrhoeae, as well as gram-positive and gram-negative bacteria such as Staphylococcus aureus, Streptoc Moreover, in vitro testing of Acos 500 mg shown action against Campylobacter sp., Toxoplasma gondii, Treponema pallidum, Mycoplasma pneumoniae, Legionella pneumophila, and hominins.Dosage of Acos 500 mgAdult: 500 mg once daily orally for 3 days or 500 mg once on day 1, then 250 mg once on days 2-5 for 4 days. For sexually transmitted diseases caused by Chlamydia trachomatis in adults, the dose is 1 gm given as a single dose or 500 mg once on day 1, followed by 250 mg once daily for next 2 days may also be given. Children: 10 mg/kg body weight once daily for 3 days for child over 6 months 200 mg (1 teaspoonful) for 3 days if body weight is 15-25 kg 300 mg (1? teaspoonfuls) for 3 days if body weight is 26-35 kg; 400 mg (2 teaspoonfuls) for 3 days if body weight is 36-45 kg. In typhoid fever, 500 mg (21/2 teaspoonfuls) once daily for 7-10 days is given.Administration of Acos 500 mgProcedure for reinstatement after suspension- Step 1: Thoroughly shake the bottle to break up the powder. Step 2: Fill the bottle with boiled and cooled water to the watermark on the label. Step 3: Mix the powder and water thoroughly to combine. Take Acos 500 mg at least one hour before or two hours after eating.Interaction of Acos 500 mgWhen food and antacids are present, Acos 500 mg absorption is lessened. Due to the potential for ergotism brought on by an interaction between Acos 500 mg and the cytochrome P-450 system, Acos 500 mg should be avoided in patients who are receiving ergot alkaloids. With co-administration, care should be taken since macrolides raise the plasma levels of cyclosporin and digoxin. Warfarin, Theophylline, Carbamazepine, Methylprednisolone, or Cimetidine have not been found to interact with Acos 500 mg.ContraindicationsThose who are hypersensitive to Acos 500 mg or any other macrolide antibiotic should not take Acos 500 mg. Ergot derivatives and Acos 500 mg should not be administered together. Those with liver disorders should not use Acos 500 mg.Side Effects of Acos 500 mgLow-frequency side effects are experienced after taking Acos 500 mg. A therapeutic withdrawal will reverse the adverse effects, which include nausea, vomiting, abdominal pain or cramps, flatulence, diarrhea, headaches, and skin rashes.Pregnancy & LactationThe Acos 500 mg pregnancy category is B. Studies on animal reproduction have shown that Acos 500 mg has no evidence of harming the fetus. Pregnant women have not been the subject of any good, controlled studies. Acos 500 mg should only be used during pregnancy if no other suitable options are available, as research on animal reproduction are not always indicative of human response. The presence of Acos 500 mg in breast milk is unknown. Hence, when giving Acos 500 mg to nursing mothers, care should be taken.Precautions & WarningsIt is advised to keep an eye out for any superinfection with non-susceptible organisms, such as fungus when using any antibiotic. Those with renal impairment don't require a dose adjustment.Overdose Effects of Acos 500 mgThere is no information on Acos 500 mg overdosage. Macrolide antibiotic overdose symptoms can include hearing loss, extreme nausea, vomiting, and diarrhea. The use of gastric lavage and other supportive treatments is advised.Storage ConditionsKeep dry and away from heat and light. Keep out of children's reach.
Acos500 mg
Original price was: ₦3,034.35.₦2,791.80Current price is: ₦2,791.80.
9.33217
0.00003
0.00080
0.01854
2.09682
-
Sale
Acteria (For kids)4 billion/sachet
Original price was: ₦2,585.00.₦2,378.20Current price is: ₦2,378.20.
7.94963
0.00002
0.00068
0.01580
1.78618
-
SaleActeria Femina 2.3 BillionIt is indicated for vaginal irritation, vaginal discomfort, reduction of colonization of bad bacteria & yeast in the vagina. pH protection of vagina against imbalances. Re-establishment & maintenance of good bacteria in the vagina. It is also indicated for urinary tract infection.CompositionEach capsule contains 2.3 billion CFU of- Lactobacillus reuteri RC-14 Lactobacillus rhamnosus GR-1 Theropeutic ClassHerbal and Nutraceuticals, ProbioticPharmacologyA combination of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 has been associated with support of the female urogenital tracts of teens, premenopausal and post menopausal women.Dosage & Administration of Acteria Femina 2.3 BillionTake 1 to 2 capsules with food, preferably with breakfast daily. Or, as directed by the registered physician.Interaction of Acteria Femina 2.3 BillionNo clinically significant drug interaction has been reported.ContraindicationsThis capsule is contraindicated with known hypersensitivity to any component of the formulation.Side Effects of Acteria Femina 2.3 BillionNo clinically significant adverse reactions have been observed in therapeutic dosage. Acteria Feminas are likely safe for most people.Pregnancy & LactationIt is safe to use during pregnancy and lactation.Storage ConditionsKeep out of reach of the children. Keep away from direct sunlight. Store below 30?C in a dry place.
Acteria Femina2.3 Billion
Original price was: ₦22,000.00.₦20,240.00Current price is: ₦20,240.00.
67.65640
0.00019
0.00581
0.13444
15.20153
-
SaleActeria 4 billionEach capsule contains- Lactobacillus acidophilus (2 billion) Lactobacillus bulgaricus (1 billion) Bifidobacterium bifidum (1 billion) as a 4 billion Acteria and Fructo-oligosaccharides (100 mg). CompositionEach capsule contains- Lactobacillus acidophilus (2 billion) Lactobacillus bulgaricus (1 billion) Bifidobacterium bifidum (1 billion) as a 4 billion Acteria and Fructo-oligosaccharides (100 mg). DescriptionActerias are defined as live microorganisms, including Lactobacillus species, Bifidobacterium species and yeasts, which may beneficially affect the host upon ingestion by improving the balance of the intestinal microflora. Lactobacillus acidophilus is one of the several bacteria in the genus Lactobacillus. It gets its name from lacto-meaning milk, bacillus-meaning rod-like in shape and acidophilus-meaning acid-loving. L. acidophilus occurs naturally in a variety of foods, including dairy, grain, meat and fish. It is also present in human (and animal) intestines, mouths and vaginas. These types of healthy bacteria inhabit in the intestines and vaginas and protect against some unhealthy organisms. Lactobacillus bulgaricus is one of several bacteria used for the production of yogurt. First identified in 1905 by the Bulgarian doctor Stamen Grigorov, it is named after Bulgaria. Morphologically, it is a gram-positive rod that may appear long and filamentous. It is also non-motile and it does not form spores. The bacterium feeds on milk and produces lactic acid which also helps to preserve the milk. It breaks down lactose and is often helpful to sufferers of lactose intolerance, whose digestive systems lack the enzymes to break down lactose to simpler sugars. While fermenting milk, Lactobacillus bulgaricus produces acetaldehyde, which perfumes yogurt. Bifidobacteria are normal inhabitants of the human and animal colon. Newborns, especially those that are breast-fed, are colonized with bifidobacteria within days after birth. Bifidobacteria were first isolated from the feces of breast-fed infants. They are gram-positive anaerobes, non-motile, non spore forming and catalase-negative. Their name is derived from the observation that they often exist in a 'Y'-shaped or bifid form. To date 30 species of bifidobacteria have been isolated.PharmacologyStudies of probiotic activity in recent years provide evidence that probiotics counter experimental and human gastrointestinal inflammation (human inflammatory bowel disease) by their effects on epithelial cell function, including epithelial cell barrier function, epithelial cytokine secretion and their antibacterial effects relating to colonization of the epithelial layer. It reduces gastrointestinal pH through stimulation of lactic-acid-producing bacteria; provide a direct antagonistic action on gastrointestinal pathogens. Moreover it competes with pathogens for binding and receptor sites. In addition, there is emerging evidence that probiotics induce regulatory T cells that act as a break on the effector T cells that would otherwise cause inflammation. Lactobacillus acidophilus and Bifidobacterium bifidum appear to enhance the nonspecific immune phagocytic activity of circulating blood granulocytes. This effect may account, in part, for the stimulation of IgA responses in infants infected with rotavirus. Lactic acid bacteria, like strains of Lactobacillus acidophilus, Lactobacillus bulgaricus have also demonstrated antioxidant ability. Mechanisms include chelation of metal ions (iron, copper), scavenging of reactive oxygen species and reducing activity.Dosage & Administration of Acteria 4 billion1 or 2 probiotics capsules 3 times daily or as directed by the physician.ContraindicationsThe use of probiotics is not advised in patients at risk of opportunistic infections and in those with badly damaged GI tracts.Side Effects of Acteria 4 billionNo known toxicity or side-effects.Pregnancy & LactationProbiotics are unlikely to reach the systemic circulation of the fetus & therefore are unlikely to cause harm. Probiotics are unlikely to be transferred into breast milk.Storage ConditionsStore below 25?C, dry place and away from direct sunlight. Keep out of reach of children.
Acteria4 billion
Original price was: ₦24,750.00.₦22,770.00Current price is: ₦22,770.00.
76.11345
0.00021
0.00654
0.15124
17.10172
-
Sale
Actifol5 mg
Original price was: ₦4,950.00.₦4,455.00Current price is: ₦4,455.00.
14.89176
0.00004
0.00128
0.02959
3.34599
-
SaleActose 30 mgActose 30 mg is indicated as an adjunct to diet and exercise to improve glycaemic control in patients with type II diabetes (NIDDM). Actose 30 mg is indicated for monotherapy and also indicated for use in combination with sulphonylurea, Metformin or Insulin when diet and exercise plus the single agent does not result in adequate glycaemic control.Theropeutic ClassThiazolidinedione GroupPharmacologyActose 30 mg is a preparation of Actose 30 mg which is a member of the newest class of oral antidiabetic agent called thiazolidinediones. It depends on the presence of Insulin for its mechanism of action. Actose 30 mg decreases Insulin resistance in the periphery and in the liver, resulting in increased Insulin dependent glucose disposal and decreased hepatic glucose output. It also improves abnormality in lipid metabolism by activating peroxisome proliferator activated receptor gamma (PPAR-?).Dosage & Administration of Actose 30 mgActose 30 mg can be taken once daily without regard to meals. The management of antidiabetic therapy should be individualized. Actose 30 mg monotherapy may be initiated at 15 mg or 30 mg once daily dosages in patients not adequately controlled with diet and exercise alone. For patients who respond inadequately to the initial dose of Actose 30 mg, the dose can be increased up to 45 mg once daily. For patients not responding adequately to monotherapy, combination therapy should be considered.Maximum recommended daily dose of Actose 30 mg should not exceed 45 mg since doses higher than 45 mg have not been studied in placebo controlled clinical studies. Besides, no placebo controlled clinical studies of more than 30 mg once daily have been conducted in combination therapy.Dosage of Actose 30 mgActose 30 mg can be taken once daily without regard to meals. The management of antidiabetic therapy should be individualized. Actose 30 mg monotherapy may be initiated at 15 mg or 30 mg once daily dosages in patients not adequately controlled with diet and exercise alone. For patients who respond inadequately to the initial dose of Actose 30 mg, the dose can be increased up to 45 mg once daily. For patients not responding adequately to monotherapy, combination therapy should be considered.Maximum recommended daily dose of Actose 30 mg should not exceed 45 mg since doses higher than 45 mg have not been studied in placebo controlled clinical studies. Besides, no placebo controlled clinical studies of more than 30 mg once daily have been conducted in combination therapy.Interaction of Actose 30 mgAdministration of thiazolidinediones with an oral contraceptive containing ethinyl oestradiol and norethindrone reduces the plasma concentration of both hormones by approximately 30% which could result in loss of contraception.ContraindicationsActose 30 mg is contraindicated in patients with known hypersensitivity to any of its components.Side Effects of Actose 30 mgThe overall incidence and types of adverse events reported in placebo controlled clinical trials of Actose 30 mg monotherapy at doses of 7.5 mg, 15 mg, 30 mg or 45 mg once daily are upper respiratory tract infection (13.2%), headache (9.1%), sinusitis (6.3%), myalgia (5.4%), tooth disorder (5.3%), and pharyngitis (5.1%).Pregnancy & LactationPregnancy: There are no adequate and well controlled studies in pregnant women. Actose 30 mg should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.Lactation: It is not known whether Actose 30 mg is secreted in human milk. As many drugs are excreted in human milk, it should not be administered to a lactating women.Precautions & WarningsActose 30 mg exerts its antihyperglycaemic effect only in the presence of Insulin. Therefore, it should not be used in Type 1 diabetes or for the treatment of diabetic ketoacidosis. Actose 30 mg should be used with caution in case of combination antidiabetic therapy and hepatic insufficiency. Liver enzyme should be monitored regularly.Storage ConditionsStore at 25? C.Drug ClassesThiazolidinedione GroupMode Of ActionActose 30 mg is a preparation of Actose 30 mg which is a member of the newest class of oral antidiabetic agent called thiazolidinediones. It depends on the presence of Insulin for its mechanism of action. Actose 30 mg decreases Insulin resistance in the periphery and in the liver, resulting in increased Insulin dependent glucose disposal and decreased hepatic glucose output. It also improves abnormality in lipid metabolism by activating peroxisome proliferator activated receptor gamma (PPAR-?).PregnancyPregnancy: There are no adequate and well controlled studies in pregnant women. Actose 30 mg should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.Lactation: It is not known whether Actose 30 mg is secreted in human milk. As many drugs are excreted in human milk, it should not be administered to a lactating women.
Actose30 mg
Original price was: ₦825.00.₦742.50Current price is: ₦742.50.
2.48196
0.00001
0.00021
0.00493
0.55766
-
SaleActrapid Flexpen 100IU/mlTreatment of all type 1 diabetic patient. treatment for those with type 2 diabetes whose blood sugar cannot be sufficiently controlled by diet or oral hypoglycemic medications. for the initial stabilization of diabetes in people with diabetic ketoacidosis, hyperosmolar non-ketotic syndrome, and during stressful times like serious illnesses and major surgery for people with diabetes. gestational diabetes treatment.Theropeutic ClassRapid Acting InsulinPharmacologyThe ability of insulin to connect to receptors on muscle and fat cells and to simultaneously restrict the liver's ability to release glucose are what cause it to drop blood sugar levels. Long-acting insulin is called Insulatard. The action begins within one and a half hours, has its peak effect within four to twelve hours, and lasts for roughly twenty-four hours. The half-life of insulin in the blood is only a few minutes. As a result, only the features of an insulin preparation's absorption dictate its time-action profile. Many elements have an impact on this process (e.g. insulin dosage, injection route, and site, the thickness of subcutaneous fat, and type of diabetes).Dosage of Actrapid Flexpen 100IU/mlUse your insulin exactly as directed by your doctor, adjusting the dosage as necessary. If you're unsure, ask your doctor, pharmacist, or nurse. Within 30 minutes of the injection, consume a meal or snack that contains carbs to prevent low blood sugar. If your doctor doesn't instruct you to, don't adjust your insulin. Your doctor may need to change your dose if you were switched from one brand or kind of insulin to another.Administration of Actrapid Flexpen 100IU/mlfor usage beneath the skin. Typically, Insulatard is injected subcutaneously into the thigh. If more practical, the deltoid area, gluteal area, or abdominal wall may also be employed. In comparison to the other injection locations, the thigh's subcutaneous injection causes a slower and less varied absorption. Unintentional intramuscular injection is less likely when the skin fold is injected into. To ensure that the entire dosage is injected, keep the needle subcutaneously for at least 6 seconds. To prevent lipodystrophy, injection sites should be rotated within anatomical regions. Never inject insulin suspensions intravenously. A package booklet for Insulatard contains comprehensive usage instructions that must be followed. The vials are meant to be used with equivalent unit insulin syringes. When two types of insulin are mixed, draw the amount of fast-acting insulin first, followed by the amount of long-acting insulin.Side Effects of Actrapid Flexpen 100IU/mlHypoglycemia, or low blood sugar, is a relatively frequent adverse consequence. More than one in ten persons might be impacted. Low blood sugar symptoms include cold perspiration, chilly pale skin, headache, rapid heartbeat, nausea, extreme hunger, brief changes in vision, fatigue, unusual weakness, anxiety or tremor, feeling agitated, feeling confused, and difficulty focusing.Pregnancy & LactationBefore using this medication, consult your doctor if you are pregnant, suspect you may be pregnant, or are planning a pregnancy. You can use this insulin while you're pregnant. You might need to adjust your insulin dosage both during pregnancy and after birth. Careful control of your diabetes, particularly prevention of hypoglycaemia, is important for the health of your baby. The use of this insulin during breastfeeding is not restricted.Precautions & WarningsIf you experience issues with your adrenal, pituitary, thyroid, or liver glands. If you decide to vary your typical diet or engage in more exercise than usual, as these actions may have an impact on your blood sugar level. Continue taking your insulin and see a doctor if you feel sick. Traveling across time zones when visiting another country could change your demand for insulin and the timing of this.Storage ConditionsKeep refrigerated at 2?C to 8?C. Avoid touching the cooling device. Avoid freezing.Use In Special PopulationsUsage in children and adolescents: Children and adolescents may use this. Usage with specific patient populations You should check your blood sugar more frequently and talk to your doctor about adjusting your insulin dosage if you have impaired kidney or liver function or if you are over 65.
Actrapid Flexpen100IU/ml
Original price was: ₦30,250.00.₦28,737.50Current price is: ₦28,737.50.
96.06105
0.00027
0.00826
0.19088
21.58369